Figures & data
Figure 1. Expression from DNA vaccine plasmids in 293T cells. (a) Expression of recombinant VEGFR2 protein examined by flow cytometry. (b) Protein expression of recombinant IL-12 assayed by ELISA.
Figure 2. Anti-VEGFR2 antibody production in mice following treatment with the DNA vaccine. (a) Kinetics of the VEGFR2-specific antibody response. (b) VEGFR2-specific antibody titres in the groups of mice.
Figure 3. ELISPOT assay. (a) VEGFR2-specific IFN-γ ELISPOT assay of splenocytes from vaccinated and mock-vaccinated mice harvested 2 weeks after the last boost immunization. (b) Analysis of the spot frequencies of VEGFR2-specific IFN-γ T-cells in the groups of mice.
Figure 4. Anti-tumour efficacy of DNA vaccines in a tumour-bearing mouse model after immunization. Growth curve of a B16-F10-VEGFR2 tumour (a); mean tumour weight (b); and tumour growth inhibition rate (c) on day 50 after vaccination.
